Latest Cost Management News

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Big River Industries reports a 4.9% sales decline year-to-date but highlights stabilizing revenue and resilient margins, with a cautious outlook on residential recovery and steady commercial demand.

BetMakers Technology Group kicks off FY26 with a strong financial turnaround and strategic advances, including a promising acquisition and digital wagering expansion in Nevada.

Big River Industries faced a tough FY2025 with subdued residential demand but showed resilience through cost control and cash generation. The company declared a modest dividend and announced key board changes as it eyes recovery.

BetMakers Technology Group has reported a remarkable 361% growth in adjusted EBITDA for Q1 FY26, driven by strong revenue gains and operational efficiencies, while advancing its strategic expansion into the Las Vegas racing market.

Syntara Limited reports encouraging Phase 2a results for amsulostat in myelofibrosis, with significant symptom relief and spleen volume reduction sustained over 12 months, alongside new clinical trial initiations and a solid cash position.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 197% surge in net profit for the first nine months of 2025, driven by robust gold, nickel, and bauxite sales alongside strategic downstreaming and operational efficiencies.

ikeGPS Group reports a robust first half of FY26 with a 47% increase in subscription revenue exit run rate and launches PolePilot™, an AI-driven automation tool enhancing utility network analysis.

Richmond Vanadium Technology reports solid progress in its Queensland vanadium project, advancing environmental approvals and feasibility studies while strengthening key industry collaborations.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Pureprofile Limited has reported record Q1 FY26 revenue and EBITDA growth, with international markets overtaking its traditional ANZ base for the first time. The company’s AI-driven platform innovations and global expansion strategy are driving this milestone.

Cann Group Limited announces a transformative $9 million capital raise alongside a major debt restructure, positioning the medicinal cannabis pioneer for profitability in FY26.